Steven Knapper

5.7k citations

91 papers · 2.4k indexed · 1 hit paper · h-index 23

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 74
- Acute Myeloid Leukemia Research 62
- Chronic Myeloid Leukemia Treatments 23
- Multiple Myeloma Research and Treatments 17
Genetics 39
- Myeloproliferative Neoplasms: Diagnosis and Treatment 24
- Chronic Lymphocytic Leukemia Research 13

Co-authors: Alan K. Burnett (31 shared papers)Mark J. Levis (9 shared papers)Richard E. Clark (10 shared papers)Donald Small (4 shared papers)Robert K. Hills (22 shared papers)Nigel H. Russell (29 shared papers)Mary Frances McMullin (12 shared papers)Amanda Gilkes (20 shared papers)
Journals: Blood (42 papers)British Journal of Haematology (15 papers)HemaSphere (6 papers)Leukemia (4 papers)Blood Advances (3 papers)
Partner nations: United Kingdom United States Denmark

In The Last Decade

Steven Knapper

86 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial 2015 · 346 citations

Peers

Countries citing papers authored by Steven Knapper

Since Specialization

Citations

This map shows the geographic impact of Steven Knapper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Knapper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Knapper more than expected).

Fields of papers citing papers by Steven Knapper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Knapper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Knapper. The network helps show where Steven Knapper may publish in the future.

Co-authors

The 25 scholars most cited alongside Steven Knapper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Knapper Line = papers co-authored together Steven Knapper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial The Lancet Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, David Bowen, Jonathan Kell, Steven Knapper, Yvonne G Morgan, Jennie Lok, Angela Grech, Gail Jones, Asim Khwaja, Lone S. Friis, Mary Frances McMullin, Ann Hunter, Richard E. Clark, David Grimwade Hit paper breakdown →	2015	346
2	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood ·Steven Knapper, Alan K. Burnett, Tim Littlewood, William J. Kell, Sam Agrawal, Raj Chopra, Richard E. Clark, Mark J. Levis, Donald Small	2006	323
3	FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo Blood ·Takashi Sato, Xiaochuan Yang, Steven Knapper, P. Bruce White, B. Douglas Smith, Steven Galkin, Donald Small, Alan Burnett, Mark J. Levis	2011	191
4	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML Blood ·Steven Knapper, Nigel H. Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Helmut König, Mark J. Levis, Alan K. Burnett	2016	120
5	The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases Blood ·Steven Knapper, Ken Mills, Amanda Gilkes, Steve J. Austin, V. Walsh, Alan K. Burnett	2006	101
6	Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival Blood ·Alan K. Burnett, Nigel H. Russell, Ann E. Hunter, Donald Milligan, Steven Knapper, Keith Wheatley, John Yin, Mary Frances McMullin, Sahra Ali, David Bowen, Robert K. Hills	2013	99
7	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline British Journal of Haematology ·Mary Frances McMullin, Claire Harrison, Sahra Ali, Catherine Cargo, Frederick Chen, Joanne Ewing, Mamta Garg, Anna L. Godfrey, Steven Knapper, Donal P. McLornan, Jyoti Nangalia, Mallika Sekhar, Frances Wadelin, Adam J. Mead	2018	94
8	Guideline for the investigation and management of eosinophilia British Journal of Haematology ·Nauman M. Butt, Jonathan Lambert, Sahra Ali, Philip Beer, Nicholas C.P. Cross, Andrew Duncombe, Joanne Ewing, Claire Harrison, Steven Knapper, Donal P. McLornan, Adam J. Mead, Deepti Radia, Barbara J. Bain	2017	83
9	Guideline for the diagnosis and management of myelofibrosis British Journal of Haematology ·John T. Reilly, Mary Frances McMullin, Philip Beer, Nauman M. Butt, Eibhlin Conneally, Andrew Duncombe, Anthony R. Green, N. George Michaeel, Maria Gilleece, Georgina Hall, Steven Knapper, Adam J. Mead, Ruben A. Mesa, Mallika Sekhar, Bridget S. Wilkins, Claire Harrison	2012	71
10	A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis British Journal of Haematology ·Mary Frances McMullin, Adam J. Mead, Sahra Ali, Catherine Cargo, Frederick Chen, Joanne Ewing, Mamta Garg, Anna L. Godfrey, Steven Knapper, Donal P. McLornan, Jyoti Nangalia, Mallika Sekhar, Frances Wadelin, Claire Harrison, (unknown)	2018	70
11	Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial British Journal of Haematology ·Adam J. Mead, Dragana Milojković, Steven Knapper, Mamta Garg, Joseph Chacko, Mira Farquharson, John Liu Yin, Sahra Ali, Richard E. Clark, Chris Andrews, Meryem Ktiouet Dawson, Claire Harrison	2015	68
12	A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia British Journal of Haematology ·Christen Lykkegaard Andersen, Mary Frances McMullin, Elisabeth Ejerblad, Sonja Zweegman, Claire Harrison, Savio Fernandes, D. Bareford, Steven Knapper, Jan Samuelsson, Eva Löfvenberg, Olle Linder, Björn Andréasson, Erik Ahlstrand, Morten K. Jensen, Ole Weis Bjerrum, Hanne Vestergaard, Herdis Larsen, Tobias Wirenfeldt Klausen, Torben Mourits‐Andersen, Hans Carl Hasselbalch	2013	56
13	Evidence of Person-to-Person Transmission of Oseltamivir-Resistant Pandemic Influenza A(H1N1) 2009 Virus in a Hematology Unit The Journal of Infectious Diseases ·Catherine Moore, Mónica Galiano, Angie Lackenby, Tamir Abdelrahman, Rosemary A. Barnes, M.R. Evans, Chris Fegan, Susannah Froude, Mark Hastings, Steven Knapper, Emma Litt, Nicola Price, R Salmon, Mark Temple, Eleri Davies	2010	50
14	Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia Leukemia ·Naeem Khan, Robert K. Hills, Paul Virgo, Stephen Couzens, Nithiya Clark, Amanda Gilkes, Peter Richardson, Steven Knapper, David Grimwade, Nigel H. Russell, Alan K. Burnett, Sylvie Freeman, (unknown)	2016	50
15	FLT3 inhibition in acute myeloid leukaemia British Journal of Haematology ·Steven Knapper	2007	49
16	Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low‐dose total body irradiation, cyclophosphamide and Campath British Journal of Haematology ·George S. Vassiliou, David Webb, Derwood Pamphilon, Steven Knapper, Paul Veys	2001	46
17	The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine Haematologica ·Elisabeth Walsby, Steven Coles, Steven Knapper, Alan K. Burnett	2010	45
18	Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia Leukemia ·Bader S. Alanazi, Chinmay Munje, Namrata Rastogi, Andrew J.K. Williamson, Samuel Taylor, Paul S. Hole, Marie Hodges, Michelle J. Doyle, Sarah M. Baker, Amanda Gilkes, Steven Knapper, Andrew Pierce, Anthony D. Whetton, Richard L. Darley, Alex Tonks	2019	44
19	Novel therapies for children with acute myeloid leukaemia Leukemia ·Andrew S. Moore, Pamela Kearns, Steven Knapper, Andrew D.J. Pearson, C. Michel Zwaan	2013	40
20	The clinical development of FLT3 inhibitors in acute myeloid leukemia Expert Opinion on Investigational Drugs ·Steven Knapper	2011	39

About Steven Knapper

Steven Knapper is a scholar working on Hematology, Genetics, Molecular Biology, Immunology and Public Health, Environmental and Occupational Health, having authored 91 papers that have together received 2.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (62 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers), Chronic Myeloid Leukemia Treatments (23 papers), Multiple Myeloma Research and Treatments (17 papers), Chronic Lymphocytic Leukemia Research (13 papers), Histone Deacetylase Inhibitors Research (12 papers), Acute Lymphoblastic Leukemia research (11 papers) and Protein Degradation and Inhibitors (10 papers). The work is most often cited by research in Hematology (1.7k citations), Genetics (825 citations), Molecular Biology (1.2k citations), Rheumatology (235 citations) and Biochemistry (82 citations). Steven Knapper has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Alan K. Burnett, Mark J. Levis, Richard E. Clark, Donald Small, Robert K. Hills, Nigel H. Russell, Mary Frances McMullin, Amanda Gilkes, Raj Chopra and William J. Kell. Their work appears in journals such as Blood, British Journal of Haematology, HemaSphere, Leukemia and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact